Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04876248 · ClinicalTrials.gov registry record · Phase 2
Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant
A Phase 2 study of Plasma Cell Myeloma, sponsored by Roswell Park Cancer Institute.
- Active
- Registry status
- Phase 2
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT04876248: Active Phase 2 study of Plasma Cell Myeloma, sponsored by Roswell Park Cancer Institute.
NCT04876248 is a Phase 2 study of Plasma Cell Myeloma that is active but no longer recruiting, run by Roswell Park Cancer Institute. The registered enrollment target is 4 participants, below the 208-participant average among 32 other Plasma Cell Myeloma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04876248, a Phase 2 study of Plasma Cell Myeloma, is active but no longer recruiting, sponsored by Roswell Park Cancer Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial investigates the effect of belantamab mafodotin and lenalidomide on minimal residual disease negative rates in patients with multiple myeloma with minimal residual disease positive after stem cell transplant. Belantamab mafodotin is a monoclonal antibody, called belantamab, linked to a chemotherapy drug, called mafodotin. Belantamab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as B-cell maturation antigen (BCMA) receptors, and delivers mafodotin to kill them. Lenalidomide may help block the formation of growths that may become cancer, and is used as a standard of care treatment for multiple myeloma. Giving belantamab mafodotin and lenalidomide may help to maintain minimal residual disease negativity in patients with multiple myeloma.
Primary Outcome
A 90% confidence interval about true 6-month post-consolidation MRD negative rate will be obtained.
Conditions Studied
Interventions
- DRUG Lenalidomide
- BIOLOGICAL Belantamab Mafodotin
Study Locations (1)
New York
- Roswell Park Cancer Institute - Buffalo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2024-08-19 |
| Est. Completion | 2026-09-01 |
| Phase | Phase 2 |
What the registry record for NCT04876248 still lists
NCT04876248 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 208-participant average among 32 other Plasma Cell Myeloma trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Plasma Cell Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Lenalidomide is the first listed.
NCT04876248 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04876248 about?
NCT04876248 is a clinical study titled "Belantamab Mafodotin and Lenalidomide for the Treatment of Multiple Myeloma in Patients With Minimal Residual Disease Positive After Stem Cell Transplant". This phase II trial investigates the effect of belantamab mafodotin and lenalidomide on minimal residual disease negative rates in patients with multiple myeloma with minimal residual disease positive after stem cell transplant. Belantamab mafodotin is a monoclonal antibody, called belantamab, linke...
What is the current status of trial NCT04876248?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 4 participants. The study started on 2024-08-19. Estimated completion is 2026-09-01.
What conditions does trial NCT04876248 study?
This clinical trial studies the following conditions: Plasma Cell Myeloma.
What interventions are being tested in trial NCT04876248?
The interventions under investigation include: Lenalidomide (DRUG), Belantamab Mafodotin (BIOLOGICAL).
Who is sponsoring clinical trial NCT04876248?
This trial is sponsored by Roswell Park Cancer Institute, which has 365 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04876248 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plasma Cell Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04876248's enrollment target sits among peer trials
4 33rd of 32 the lowest of 32 other Plasma Cell Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Plasma Cell Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
RECRUITING · Phase 2
-
Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Lenalidomide Maintenance in Plasma Cell Myeloma
ACTIVE NOT RECRUITING · Phase 2
-
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI